Introducing MolecuLight i:X

Handheld Technology to Visualize Bacteria in Wounds


Portable, touch-screen
with an intuitive interface.


Allows for more targeted treatment protocols by knowing exactly where the bacteria is.


Instantly detects and reveals potentially harmful levels of bacteria.



No contrast agents
and no patient contact required.


Immediately know where to sample, where to debride and if you need an expensive antimicrobial product.


Allows clinicians to focus on harmful bacteria with the guidance of fluorescence imaging.

US FDA De Novo approval pending - the MolecuLight i:XTM Imaging Device is not available in the US.

Clinical Evidence

Screenshot from 2017-04-07 21:57:24Identification of moderate/ heavy levels of potentially harmful bacteria.1

Screenshot from 2017-04-07 21:57:24Identified moderate-to-heavy levels of Methicillin Resistant Staphylococcus Aureus (MRSA) where standard of care did not.1

Screenshot from 2017-04-07 21:57:24More accurate swabbing results than the current gold standard.2

Screenshot from 2017-04-07 21:57:24Increased rate of wound closure in a statistically significant manner compared with the control (non-guided) periods.2

Screenshot from 2017-04-07 21:57:24Differentiation of Pseudomonas Aeruginosa from other pathogenic bacteria.2

Screenshot from 2017-04-07 21:57:24Detection of wound subsurface heavy bacterial load and subclinical local infection in asymptomatic patients.3

1DaCosta RS et al; unpublished data, Clinical Trials. Gov NCT01651845
2DaCosta RS et al., PLoS ONE (2015) 10(3): e0116623
3Wu CT et al., International Wound Journal (2015), doi: 10.1111/iwj.12451